News | May 11, 2024
Hester Biosciences posts Q4 FY24 consolidated profit increases to Rs. 4.95 Cr
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
The USFDA has issued 5 observations pursuant to the completion of audit
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Global Phase-3 study initiation expected in the second half of 2024
Subscribe To Our Newsletter & Stay Updated
